Why RAPT Therapeutics Stock Is Crushing It Today fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
Sonelokimab shows promise in Phase II psoriasis trial
4
New Phase IIb data shows the highest dose of MoonLake Immunotherapeutics’ Tri-specific Nanobody
® sonelokimab was able to induce total skin clearance in 57 percent of patients with moderate to severe psoriasis. According to MoonLake, not only did sonelokimab show impressive efficacy, it also had a favourable safety profile and numerically outperformed the trial’s active control, secukinumab. The results of the trial were published in
Sonelokimab is an investigational interleukin 17 (IL-17)A/IL-17F inhibitor with an albumin binding site which is being developed as a treatment for inflammatory skin and joint diseases. According to its developers, it has the potential to facilitate deep tissue penetration in the skin and joints and has clinically demonstrated potential to allow better disease control in dermatology and rheumatology patients.
Ichnos Sciences Presents Positive Data From Ongoing Phase 2b Study Of Telazorlimab In Atopic Dermatitis At The 2021 SID Virtual Meeting streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Share:
Extended safety analysis across eight studies helps further define the known safety profile of Olumiant 2-mg in atopic dermatitis
TORONTO, April 30, 2021 /CNW/ - Through new analyses of BREEZE-AD5 Phase 3 clinical trial data and an extended safety analysis across multiple trials, Eli Lilly and Company and Incyte s Olumiant® (baricitinib) 2-mg tablet taken once daily showed improvement in key measured treatment outcomes compared to placebo, and helped further characterize the long-term safety profile in adults with moderate- to severe atopic dermatitis (AD). In one BREEZE-AD5 analysis, Olumiant provided concurrent improvements in the severity and extent of AD, other key symptoms and quality of life as early as one week, as measured by per cent change from baseline compared to placebo. In a separate BREEZE-AD5 analysis, adults with AD on 10-50% of their bodies at baseline who were treated with Olumiant showed significant improvements in the severity and extent of disease comp